Change over period: —
NSE · HIKAL
HIKAL LTD.
-12.9% from the 52-week high · +51.7% above the low
Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,142 full-time employees. The firm operates through two segments: pharmaceuticals and crop protection. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. The Company’s products and services include gabapentin; thiabendazole, and diuron contract development and custom manufacturing of intermediates; application programming interface (APIs); and artificial intelligence (AI’s). The firm supplies its products to customers across the globe in the United States, Japan, Europe, Canada, Southeast Asia, Latin American, India and RoW.
The short version. HIKAL LTD. reported revenue of ₹434 crore for Sep 2026, up 36.5% from a year earlier. Net profit was ₹-6 crore. Return on equity was -4.1% in Mar 2026. Promoter holding was 68.85% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
HIKAL LTD. trades 12.9% below its 52-week high and 51.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹434 cr.
9.6 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 403 | 519 | 494 | 318 | 380 | 552 | 448 |
| Net profit | -6 | -7 | 14 | -6 | -35 | -22 | 50 | 17 |
| Net margin % | -1.4 | -1.8 | 2.8 | -1.2 | -11.0 | -5.9 | 9.1 | 3.8 |
| EPS (₹) | -0.49 | -0.6 | 1.17 | -0.48 | -2.83 | -1.82 | 4.07 | 1.39 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1713 | 1860 | 1785 | 2023 | 1943 | 1720 | 1507 | 1590 |
| Net profit | -49 | 91 | 70 | 78 | 161 | 133 | 84 | 103 |
| Net margin % | -2.8 | 4.9 | 3.9 | 3.9 | 8.3 | 7.7 | 5.6 | 6.5 |
| EPS (₹) | -3.96 | 7.36 | 5.64 | 6.36 | 13.02 | 10.8 | 6.85 | 8.36 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -4.1% in Mar 2026; debt to equity is 0.57.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -4.1 | 7.2 | 5.9 | 6.9 |
| Return on capital % | -1.0 | 11.4 | 8.8 | 8.9 |
| EBITDA margin % | 8.6 | 17.9 | 15.1 | 12.9 |
| Net margin % | -2.8 | 4.9 | 3.9 | 3.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -5.3% | -0.0% |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 4.79 pts over 8 quarters.
Up 1.84 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 | 68.85 | 0.0 |
| FII | 6.06 | 5.69 | 5.36 | 4.23 | 2.3 | 1.43 | 0.99 | 1.27 | -4.79 |
| DII | 3.48 | 3.8 | 4.02 | 5.16 | 7.05 | 7.2 | 7.24 | 5.32 | +1.84 |
| Public | 21.61 | 21.66 | 21.77 | 21.76 | 21.79 | 22.52 | 22.93 | 24.56 | +2.95 |
Mutual fund holdings · Oct 2026
4 schemes hold this stock
4 the month before.
- ICICI Prudential Healthcare Fund0.89% of NAV
- TATA SMALL CAP FUND0.59% of NAV
- Motilal Oswal BSE Healthcare ETF0.05% of NAV
- Bandhan BSE Healthcare Index Fund0.05% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for HIKAL LTD. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about HIKAL LTD.
What is the HIKAL LTD. share price?
HIKAL LTD. (HIKAL) last closed at ₹222.06, down 0.49% on the day. Its 52-week range is ₹147.08 to ₹256.15.
What is the market cap of HIKAL LTD.?
HIKAL LTD. has a market capitalisation of about ₹2,754 crore.
How are HIKAL LTD.'s latest results?
HIKAL LTD. reported revenue of ₹434 crore for Sep 2026, up 36.5% from a year earlier. Net profit was ₹-6 crore. Return on equity was -4.1% in Mar 2026. Promoter holding was 68.85% in Sep 2026, up 0.00 points over 8 quarters.
Who owns HIKAL LTD.?
As of Sep 2026, shareholding was: Promoter 68.85%, FII 1.27%, DII 5.32%, Public 24.56%.
How many mutual funds hold HIKAL LTD.?
4 mutual fund schemes held HIKAL LTD. in October 2026. That compares with 4 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 17 Feb 2026 · Interim Dividend - Rs. 0.2
- 02 Sep 2025 · Final Dividend - Rs. 0.8
- 07 Feb 2025 · Interim Dividend - Rs. 0.6
- 04 Sep 2024 · Final Dividend - Rs. 0.6
- 20 Feb 2024 · Interim Dividend - Rs. 0.6
- 18 Sep 2023 · Final Dividend - Rs. 0.6
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.